Biosimilars: Controversies as illustrated by rhGH

Current Medical Research and Opinion

Volumn 26, Issue 5, 2010, Pages 1219-1229

  Declerck, Paul J ^a   Darendeliler, Feyza ^b   Gth, Mikls ^c   Kolouskova, Stanislava ^d   Micle, Ioana ^e,f   Noordam, Cees ^g   Peterkova, Valentina ^h   Volevodz, Natalia N ^h   Zapletalov, Jiina ⁱ   Ranke, Michael B ^j  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ISTANBUL UNIVERSITY   (Turkey)

^c State Health Centre   (Hungary)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^e VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f Louis Turcanu Emergency Children's Hospital   (Romania)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

ⁱ PALACKÝ UNIVERSITY   (Czech Republic)

^j University Childrens Hospital   (Germany)

more..

Author keywords

Biopharmaceutical; Biosimilar; Follow on biologic; Healthcare economics; Human growth hormone; Similar biological medicinal product

Indexed keywords

ALPHA2 INTERFERON; GENERIC DRUG; HUMAN GROWTH HORMONE; PLANT MEDICINAL PRODUCT; RECOMBINANT ERYTHROPOIETIN;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; BIOEQUIVALENCE; CARCINOGENICITY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GROWTH HORMONE DEFICIENCY; HUMAN; IMMUNOGENICITY; MAXIMUM PLASMA CONCENTRATION; MEDICAL SOCIETY; META ANALYSIS; MUTAGENICITY; NOTE; SYSTEMATIC REVIEW; TREATMENT INDICATION; TURNER SYNDROME;

BIOLOGICAL PRODUCTS; HUMAN GROWTH HORMONE; HUMANS; RECOMBINANT PROTEINS;

EID: 77951028492     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003719642     Document Type: Note

References (51)

1. Krysiak R, Gdula-Dymek A, Bednarska-Czerwinska A, et al. Growth hormone therapy in children and adults. Pharmacol Rep 2007;59:500-516
2. Ranke MB. New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars. Horm Res 2008;69:22-28
3. Questions and answers on generic medicines. London: Doc. Ref. EMEA/393905/2006, 2007. Available at: http://www.ema.europa.eu/pdfs/human/pcwp/ 39390506en.pdf [Last accessed 2 February 2010]
4. Crommelin DJA, Storm G, Verrijk R, et al. Shifting paradigms: biopharmaceu-ticals versus low molecular weight drugs. Int J Pharm 2003;266:3-16
5. Crommelin D, Bermejo T, Bissig M, et al. Pharmaceutical evaluation of biosi-milars: important differences from generic low-molecular-weight pharmaceuticals. EJHP-S 2005;11:11-17
6. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004;251(Suppl. 2):II4-II9
7. Guideline on similar biological medicinal products. London: CHMP/437/04 2005. Available at: http://www.ema.europa.eu/pdfs/human/biosimilar/043704en.pdf [Last accessed 2 February 2010]
8. Meredith PA. Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms. Curr Med Res Opin 2009;25:2179-2189
9. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London: EMEA/CHMP/BWP/49348/2005, 2006. Available at: http://www.ema.europa.eu/pdfs/ human/biosimilar/4934805en.pdf [Last accessed 2 February 2010]
10. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London: EMEA/CHMP/BMWP/42832/2005, 2006. Available at: http://www.ema.europa.eu/pdfs/human/biosimilar/4283205en.pdf [Last accessed 2 February 2010]
11. Pavlovic M, Girardin E, Kapetanovic L, et al. Similar biological medicinal products containing recombinant human growth hormone: European regulation. Horm Res 2008;69:14-21
12. Annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing somatropin. London: EMEA/CHMP/BMWP/94528/2005 2006. Available at: http://www.ema.europa.eu/pdfs/ human/biosimilar/9452805en.pdf [Last accessed 2 February 2010]
13. Hindmarsh PC, Dattani MT. Use of growth hormone in children. Nat Clin Pract Endocrinol Metab 2006;2:260-268
14. Bryant J, Baxter L, Cave CB, et al. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev 2007;3:CD004440
15. Baxter L, Bryant J, Cave CB, et al. Recombinant growth hormone for children and adolescents with Turner syndrome. Cochrane Database Syst Rev 2007;1:CD003887
16. Monson JP. Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol 2003;148(Suppl. 2):S9-14
17. Vimalachandra D, Hodson EM, Willis NS, et al. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev 2006; 3:CD003264
18. Darendeliler F, Karagiannis G, Wilton P, et al. Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database). Acta Paediatr 2006;95:1284-1290
19. Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res 2007; 68(Suppl. 5):41-47
20. Gutierrez LP, Koltowska-Haggstrom M, Jonsson PJ, et al. Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf 2008;17: 90-102
21. Monson JP, Bengtsson BA, Abs R, et al. Can growth hormone therapy cause diabetes? Lancet 2000;355:1728-1729
22. Kemp SF, Kuntze J, Attie KM, et al. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab 2005;90:5247-5253
23. Lamberts SW. Hypopituitary control and complications study (HypoCCS): a decade of an outcomes assessment observational study. J Endocrinol Invest 2008;31(Suppl. 9):2-5
24. SM observational registry in children treated with recombinant human growth hormone (Saizen®). Pediatr Endocrinol Rev 2009;6(Suppl. 2):278-282
25. Omnitrope European public assessment report. Revision 4-Published 23/04/2008. Scientific discussion. Available at: www.ema.europa.eu/human-docs/ PDFs/EPAR/Omnitrope/060706en6.pdf [Last accessed 2 February 2010]
26. Valtropin European public assessment report. Revision 3-Published 17/06/2009. Scientific discussion. Available at: www.ema.europa.eu/humandocs/ PDFs/EPAR/valtropin/H-602-en6.pdf [Last accessed 2 February 2010]
27. Romer T, Peter F, Saenger P, et al. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution. J Endocrinol Invest 2007; 30:578-589
28. Peterkova V, Arslanoglu I, Bolshova-Zubkovskaya E, et al. A randomized, double-blind study to assess the efficacy and safety of valtropin, a biosimilar growth hormone, in children with growth hormone deficiency. Horm Res 2007;68:288-293
29. TM in the treatment of short stature in girls with Turner's syndrome. J Pediatr Endocrinol Metab 2004;17:1429-1434
30. Humatrope summary of product characteristics. Available at: http://emc. medicines.org.uk/history/601/SPC/Humatrope+6mg,+12mg,+or+24mg+ powder+and+solvent+for+solution+for+injection [Last accessed 2 February 2010]
31. Romer T, Saenger P, Peter F, et al. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of growth hormone deficient children: results of a phase III study. Horm Res 2009; 72:359-369
32. Root AW, Kemp SF, Rundle AC, et al. Effect of long-term recombinant growth hormone therapy in children-the National Cooperative Growth Study, USA 1985-1994. J Pediatr Endocrinol Metab 1998;11:403-412
33. Bercu BB, Murray FT, Frasier SD, et al. Long-term therapy with recombinant human growth hormone (Saizen®) in children with idiopathic and organic growth hormone deficiency. Endocrine 2001;15:43-49
34. Saenger P. Current status of biosilimar growth hormone. Int J Pediatr Endocrinol 2009; published online 29 September 2009, doi:10.1155/2009/370329
35. Omnitrope drug approval package. FDA/Center for Drug Evaluation and Research, approval date 5/30/2006. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/nda/2006/021426s000TOC.cfm [Last accessed 2 February 2010]
36. Valtropin drug approval package. FDA/Center for Drug Evaluation and Research, approval date 4/19/2007. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/nda/2007/021905-valtropin-toc.cfm [Last accessed 2 February 2010]
37. Omnitrope prescribing information. FDA/Center for Drug Evaluation and Research. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2008/021426s002lbl.pdf [Last accessed 2 February 2010]
38. Valtropin prescribing information. FDA/Center for Drug Evaluation and Research. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2007/021905lbl.pdf [Last accessed 2 February 2010]
39. Follow-on protein products. Statement of Janet Woodcock before the House Committee on Oversight and Government Reform. Washington, DC, 2007 March 26. Available at: http://www.fda.gov/NewsEvents/Testimony/ucm154070.htm [Last accessed 2 February 2010]
40. Omnitrope European public assessment report. Revision 4-Published 23/04/2008. Procedural steps taken and scientific information after the authorisation. Available at: www.ema.europa.eu/humandocs/PDFs/EPAR/Omnitrope/ 060706en8.pdf [Last accessed 2 February 2010]
41. Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005;67:2346-2353
42. Ryff JC. Clinical investigation of the immunogenicity of interferon-alpha 2a. J Interferon Cytokine Res 1997;17(Suppl. 1):S29-33
43. Omnitrope summary of product characteristics. 18/03/2008 Omnitrope-H-C-607-II-09. Available at: www.ema.europa.eu/humandocs/PDFs/EPAR/ Omnitrope/H-607-PI-en.pdf [Last accessed 2 February 2010]
44. Osio D, Dahlgren J, Wikland KA, et al. Improved final height with long-term growth hormone treatment in Noonan syndrome. Acta Paediatr 2005; 94:1232-1237
45. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001;86:1868-1870
46. Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000;355:610-613
47. Blethen SL, Rundle AC. Slipped capital femoral epiphysis in children treated with growth hormone. A summary of the National Cooperative Growth Study experience. Horm Res 1996;46:113-116
48. Wyatt D. Lessons from the National Cooperative Growth Study. Eur J Endocrinol 2004;151(Suppl. 1):S55-S59
49. Tesar? V, Rychlik I. Biosimilars and renal health care in the countries of Central and Eastern Europe. Kidney Blood Press Res 2007 30(Suppl. 1) 2-5
50. Nelson WW, Frear RS. Physician attitudes toward human growth hormone products. Am J Health Syst Pharm 1999;56:51-56
51. Shine B, Musial W, Owens L, et al. Patient and parent preference for growth hormone products. Am J Health Syst Pharm 2003;60: 89-90